Group 1 - The company announced the signing of a "Maximum Financing Contract" with Shanghai Rural Commercial Bank on March 2025, indicating a strategic financial partnership [1] - To ensure the fulfillment of the financing contract, the company has signed a "Maximum Mortgage Contract," providing land and property as collateral for the credit facility [1] - The company plans to apply for a comprehensive credit limit of up to 40 million yuan after the expiration of the current credit facility, with the final credit limit and terms subject to bank approval [1] Group 2 - The mortgage guarantee is classified as a self-provided collateral, which falls within the board's review authority and does not require shareholder meeting approval [1]

Group 1 - The company Tianyu Co., Ltd. announced on August 22 that it will hold the 14th meeting of the fifth board of directors on August 22, 2025, to review a proposal for additional bank credit for its wholly-owned subsidiary, Node Pharmaceutical [1] - The company plans to apply for an additional loan credit limit of 500 million yuan (approximately 70.5 million USD) from Industrial Bank to meet the funding needs for Node Pharmaceutical's new project, which aims to produce 6 billion solid dosage forms annually [1] - After the additional credit, Node Pharmaceutical will be able to apply for a total loan credit limit of up to 900 million yuan (approximately 126.8 million USD) from Industrial Bank, with a validity period of 10 years [1] Group 2 - The company will provide joint liability guarantee for this loan, and Node Pharmaceutical will use the land use rights of the project as collateral for the loan [1] - The board of directors is requested to authorize the company's chairman to handle the signing of agreements related to the credit limit, including but not limited to credit and loan matters [1]